To address if combination therapy-mediated increases of CD4+ and CD8+ T cells are responsible for improved efficacy of combination therapy in bladder tumour, MB49 tumour-bearing mice were pretreated with specific CD4+ and/or CD8+ T-cell depleting antibodies before combination therapy. This evidence concerns the gene CD4 and urinary bladder neoplasm.